Skip to content
  • About
    • Supporter
    • Expert Index
    • Editorial Board
    • Editorial Team
    • Editorial Policy
  • Contact
  • Sign up

Visit

vjdementia
VJNeurology
Logo
  • Home (current)
  • Diseases
    Parkinson's Disease
    Multiple Sclerosis and Related Disorders
    Headache
    Amyotrophic Lateral Sclerosis
    Epilepsy
    Sleep Disorders
    Stroke
    Neuromuscular Disorders
    Movement Disorders
    View all Diseases
  • Topics
    Biology
    Diagnostics
    Trial Updates
    Treatment
    Prevention
    Surgery
    Imaging
    Genetics
    COVID-19
    View all Topics
  • Conferences
    ESOC 2022
    AAN 2022
    CONy 2022
    AD/PD 2022
    World Sleep 2022
    ACTRIMS 2022
    View all Conferences
  • Features
  • Podcasts
    • About
      • Supporter
      • Expert Index
      • Editorial Board
      • Editorial Team
      • Editorial Policy
    • Contact
    • Sign up

Levodopa

New drugs for treatment of Parkinson’s disease 1:47
New drugs for treatment of Parkinson’s disease
Fabrizio Stocchi • 18 Mar 2022
Latest developments in symptomatic treatment of Parkinson’s disease 1:47
Latest developments in symptomatic treatment of Parkinson’s disease
Fabrizio Stocchi • 18 Mar 2022
Predictors of augmentation in RLS 1:50
Predictors of augmentation in RLS
Evi Holzknecht • 14 Mar 2022
The impact of LCIG on dyskinesia duration & severity in PD 4:19
The impact of LCIG on dyskinesia duration & severity in PD
Alfonso Fasano • 22 Sep 2021
Upcoming treatments for Parkinson’s disease 1:10
Upcoming treatments for Parkinson’s disease
Zvezdan Pirtosek • 27 Sep 2021
Parkinson’s disease: what’s to come in 2022? 3:20
Parkinson’s disease: what’s to come in 2022?
Angelo Antonini • 24 Sep 2021
The current treatment landscape for PD 1:21
The current treatment landscape for PD
Caroline Tanner • 14 Sep 2021
The use of amantadine in Parkinson’s disease 2:13
The use of amantadine in Parkinson’s disease
Caroline Tanner • 14 Sep 2021
The efficacy of amantadine as an early add-on for motor complications 3:15
The efficacy of amantadine as an early add-on for motor complications
Caroline Tanner • 14 Sep 2021
Continuous dopaminergic stimulation to prevent motor complications in Parkinson’s disease 3:42
Continuous dopaminergic stimulation to prevent motor complications in Parkinson’s disease
Angelo Antonini • 24 Sep 2021
Should device-aided treatment be given earlier in Parkinson’s disease? 14:59
Should device-aided treatment be given earlier in Parkinson’s disease?
Zvezdan Pirtosek • 27 Sep 2021
LECIG for motor fluctuations in Parkinson’s disease 3:28
LECIG for motor fluctuations in Parkinson’s disease
Dag Nyholm • 24 Jun 2021
Carbidopa/levodopa enteral suspension for PD 1:38
Carbidopa/levodopa enteral suspension for PD
Gian Pal • 30 Apr 2021
Improving levodopa delivery in PD 4:28
Improving levodopa delivery in PD
Daniele Urso • 19 Feb 2021
Dopamine agonist phobia in PD 4:51
Dopamine agonist phobia in PD
Lucia Batzu • 19 Mar 2021
Treatment options for dystonia: anticholinergics, levodopa, botulinum toxin and DBS 3:57
Treatment options for dystonia: anticholinergics, levodopa, botulinum toxin and DBS
Susanne Schneider • 17 Sep 2020
  • 1
  • 2
  • Next
Journal Pages
  • Diseases
  • Topics
  • Medicines
  • Trials
  • Conferences
  • Features
Newsletter

Receive the latest news and videos from VJNeurology via email

Sign up
Contact Us

Contact us for more information

mmp logo

Magdalen Centre
The Oxford Science Park
Oxford OX4 4GA, United Kingdom

VJNeurology logo
The content of VJNeurology is intended for healthcare professionals
  • Cookie Policy
  • Privacy Policy
  • Terms of Use
  • Editorial Policy